logo
Plus   Neg
Share
Email

Under Armour Q2 Loss Narrows - Quick Facts

Under Armour, Inc. (UA,UAA) on Tuesday reported net loss for the second quarter of $17.35 million or $0.04 per share, narrower than net loss of $95.54 million or $0.21 per share in the year-ago period.

The latest quarter's results are inclusive of a negative $0.01 impact from the company's minority interest in its Japanese licensee.

Net revenue for the quarter rose 1 percent to $1.19 billion from $1.17 billion in the year-ago period. Revenue increased 3 percent on a currency neutral basis.

On average, analysts polled by Thomson Reuters expected the company to report loss of $0.05 per share for the quarter on revenues of $1.2 billion. Analysts' estimates typically exclude special items.

For fiscal 2019, Under Armour forecast revenue to increase about 3 percent to 4 percent, and earnings per share in a range of $0.33 to $0.34 inclusive of a negative impact from the company's minority interest in its Japanese licensee.

The Street expects earnings of $0.35 per share for the year on revenues of $5.38 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chipotle Mexican Grill Inc. is introducing a new protein to its menu, Carne Asada, starting this week. Carne Asada is Chipotle's newest protein addition since it reintroduced chorizo in September 2018. The Mexican food chain said that the new steak option will be available at its restaurants nationwide from Thursday, September 19, 2019. Pizza Hut has partnered with Cheez-It to launch a new item to its menu - the Stuffed Cheez-It Pizza. The pizza chain, a subsidiary of Yum! Brands, said that the new item combines Pizza Hut pizza and the Cheez-It cheese snack. Stuffed Cheez-It Pizza will be available on Pizza Hut menus nationwide for a limited-time. Pizza Hut is the official pizza sponsor of the NFL and NCAA. The U.S. Food and Drug Administration on Tuesday unveiled a new international collaboration for simultaneous review and approval of cancer drugs along with the agency's Australian and Canadian counterparts. The simultaneous approval of cancer therapies by the three regulators is intended to accelerate the process of making these new treatments available to patients around the world.
Follow RTT